Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2023 · 10-K
Revenue$9.35M$9.35M+2.5% vs Q4 2022 Net Income-$6.29M-$6.29MN/M vs Q4 2022 EPS Diluted-$0.44-$0.44N/M vs Q4 2022 Operating Income-$6,179,239N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$991,448−73.9% Margins · derivedOperating margin-66.1%−41.1 pt vs Q4 2022
Net margin-67.3%−40.5 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 13, 2024 · 73 d after period end